Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ABI-2280
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : IND Enabling
Sponsor : Adjuvant Capital
Deal Size : $31.0 million
Deal Type : Series D Financing
Antiva Biosciences Closes $31 Million Series D Equity Financing
Details : Proceeds from the financing will support the development of the company’s lead development candidate, ABI-2280, including the near-term advancement of the compound into Phase 1 and 2a clinical trials as a potential treatment for high-grade cervical int...
Product Name : ABI-2280
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 11, 2021
Lead Product(s) : ABI-2280
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : IND Enabling
Sponsor : Adjuvant Capital
Deal Size : $31.0 million
Deal Type : Series D Financing
Reset All
